| Particulars (Rupees in Crores.) | Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 |
|---|---|---|---|---|---|
Gross Sales | 9,820.77 | 9,731.76 | 8,696.66 | 8,150.33 | 6,672.85 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 9,820.77 | 9,731.76 | 8,696.66 | 8,150.33 | 6,672.85 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 347.78 | 222.67 | 147.41 | 142.13 | 186.93 |
Total Income | 10,168.55 | 9,954.43 | 8,844.07 | 8,292.46 | 6,859.78 |
Total Expenditure | 7,699.91 | 7,997.22 | 7,440.46 | 6,434.64 | 5,021.56 |
PBIDT | 2,468.64 | 1,957.21 | 1,403.61 | 1,857.82 | 1,838.22 |
Interest | 93.28 | 85.55 | 78.4 | 35.4 | 48.21 |
PBDT | 2,375.36 | 1,871.66 | 1,325.21 | 1,822.42 | 1,790.01 |
Depreciation | 244.67 | 215.87 | 232.1 | 220.82 | 206.07 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 439.35 | 338.43 | 211.04 | 318.63 | 315.42 |
Deferred Tax | -201.65 | -189.62 | -57.06 | -289.14 | -100.03 |
Reported Profit After Tax | 1,892.99 | 1,506.98 | 939.13 | 1,572.11 | 1,368.55 |
Minority Interest After NP | 33.37 | 4.77 | 25.94 | 34.07 | 23.52 |
Net Profit after Minority Interest | 1,859.62 | 1,502.21 | 913.19 | 1,538.04 | 1,345.03 |
Extra-ordinary Items | 0 | -86.7 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 1,859.62 | 1,588.91 | 913.19 | 1,538.04 | 1,345.03 |
EPS (Unit Curr.) | 155.54 | 125.64 | 76.38 | 128.64 | 112.49 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 1,850 | 1,750 | 2,000 | 1,500 | 1,250 |
Equity | 23.91 | 23.91 | 23.91 | 23.91 | 23.91 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 25.13 | 20.11 | 16.13 | 22.79 | 27.54 |
PBDTM(%) | 24.18 | 19.23 | 15.23 | 22.36 | 26.82 |
PATM(%) | 19.27 | 15.48 | 10.79 | 19.28 | 20.5 |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
